Cargando…
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning
Preconditioning, postconditioning, and remote conditioning of the myocardium enhance the ability of the heart to withstand a prolonged ischemia/reperfusion insult and the potential to provide novel therapeutic paradigms for cardioprotection. While many signaling pathways leading to endogenous cardio...
Autores principales: | Ferdinandy, Péter, Andreadou, Ioanna, Baxter, Gary F., Bøtker, Hans Erik, Davidson, Sean M., Dobrev, Dobromir, Gersh, Bernard J., Heusch, Gerd, Lecour, Sandrine, Ruiz-Meana, Marisol, Zuurbier, Coert J., Hausenloy, Derek J., Schulz, Rainer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Pharmacology and Experimental Therapeutics
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832381/ https://www.ncbi.nlm.nih.gov/pubmed/36753049 http://dx.doi.org/10.1124/pharmrev.121.000348 |
Ejemplares similares
-
IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
por: Lecour, Sandrine, et al.
Publicado: (2021) -
ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies
por: Lecour, Sandrine, et al.
Publicado: (2014) -
Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection
por: Heusch, Gerd, et al.
Publicado: (2023) -
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations
por: Hausenloy, Derek J., et al.
Publicado: (2010) -
Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting?
por: Kleinbongard, Petra, et al.
Publicado: (2020)